BERKELEY, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today the receipt of the East Bay Economic Development Alliance’s (East Bay EDA) East Bay Innovation Award for its innovation within the life science industry and unique contributions to the East Bay’s prosperity and culture of innovation. 

“We are honored to have been recognized by the East Bay EDA for our innovative approach to the treatment of cancer and for our efforts to support and nurture the continued prosperity and rich culture that makes the East Bay what it is today,” stated Stephen Isaacs, chairman, president and chief executive officer of Aduro. “It is the diversity of our community—the people, the academic institutions, and businesses—that support us in our mission to bring innovative new therapies to individuals battling cancer.  We are grateful to be in the position to make a positive difference in the lives of others, within the East Bay and beyond.”

Founded in Berkeley in 2008 and housed in an 110,853-square foot building with state-of-the art research facilities, Aduro is proud to support the local community in a variety of ways.  The company seeks to spark a lasting interest in science through its participation with the Institute for Science, Technology, Engineering, and Mathematics (STEM) Education program at California University, East Bay, as well as help create industry awareness and employment opportunities in under-represented communities through an internship program conducted in partnership with local community colleges.  Additionally, the company maintains a close relationship with local academic institutions, including the University of California at Berkeley through a research collaboration relating to their Immunotherapeutics and Vaccine Research Initiative (IVRI), an initiative focused on identifying and advancing new treatment options and preventive modalities for cancer, infectious disease and autoimmune disease. 

A corporate video about Aduro is available at

About the East Bay Economic Development Alliance (East Bay EDA)
The East Bay Economic Development Alliance is a public-private partnership founded in 1990, and serves the Bay Area’s East Bay region (Alameda and Contra Costa Counties). East Bay EDA’s mission is to be the regional voice and networking resource for strengthening the economy, building the workforce and enhancing the quality of life in the East Bay.  For more information on East Bay EDA, please go to:

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “seek,” “potential,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our annual report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264

Media Contact:
Susan Lehner
510 809 2137